6 results on '"Peters TG"'
Search Results
2. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients.
- Author
-
Kucirka LM, Peters TG, and Segev DL
- Subjects
- Adult, Comorbidity, Female, Hepacivirus isolation & purification, Humans, In Vitro Techniques, Kidney Diseases surgery, Liver Diseases surgery, Liver Diseases virology, Male, Middle Aged, Tissue Donors, Waiting Lists, Hepatitis C epidemiology, Kidney virology, Kidney Diseases epidemiology, Kidney Transplantation immunology, Liver Diseases epidemiology, Liver Transplantation immunology, Patient Selection
- Abstract
Background: Only 29% of deceased donor kidney recipients with hepatitis C virus (HCV) receive HCV-positive (HCV+) kidneys. These kidneys are discarded 2.5 times more often than their HCV-negative (HCV-) counterparts, possibly due to the sense that an HCV+ kidney may adversely affect recipient liver function. The goals of this study were to characterize liver disease in HCV+ kidney recipients and compare rates of liver-related outcomes by kidney donor HCV status., Study Design: Observational cohort study., Setting & Participants: 6,250 patients with HCV who had a kidney transplant in 1995-2008 as captured in the United Network for Organ Sharing (UNOS) database. Liver-related outcomes were assessed by cross-linking with the liver waitlist and transplant data sets., Predictor: HCV status of transplanted kidney., Outcomes: Joining the liver waitlist, receiving a liver transplant, death., Measurements: Time to event., Results: Only 63 (1%) of HCV+ kidney recipients eventually joined the liver waitlist during the 13-year study period. Those who received HCV+ kidneys had a 2.6-fold higher hazard of joining the liver list (P < 0.001); however, the absolute difference in rate of listing between recipients of HCV- and HCV+ kidneys was <2%. This is consistent with findings of only 2% lower patient survival at 3 years in HCV+ patients receiving HCV+ versus HCV- kidneys., Limitations: We lacked data for HCV viral load and genotype of both HCV+ recipients and transplanted HCV+ kidneys., Conclusions: Because transplant with an HCV+ kidney may reduce waiting-time by more than a year for an HCV+ patient and there is a high risk of kidney waitlist mortality, a 2% increased rate of adverse liver outcomes and 2% increased rate of death at 3 years should not universally preclude the use of HCV+ kidneys when the intended recipient is also HCV+., (Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
3. Racial disparities and transplantation.
- Author
-
Peters TG
- Subjects
- Black or African American statistics & numerical data, Health Services Accessibility, Hospitals statistics & numerical data, Humans, Kidney Failure, Chronic ethnology, Kidney Failure, Chronic therapy, Kidney Transplantation ethnology, Referral and Consultation statistics & numerical data, Waiting Lists, Kidney Transplantation statistics & numerical data, Racial Groups statistics & numerical data
- Published
- 2005
- Full Text
- View/download PDF
4. Late urinary tract infection after renal transplantation in the United States.
- Author
-
Abbott KC, Swanson SJ, Richter ER, Bohen EM, Agodoa LY, Peters TG, Barbour G, Lipnick R, and Cruess DF
- Subjects
- Adult, Aged, Cohort Studies, Female, Graft Survival, Humans, Kidney Transplantation mortality, Male, Medicare, Middle Aged, Postoperative Complications mortality, Proportional Hazards Models, Pyelonephritis epidemiology, Pyelonephritis mortality, Retrospective Studies, Risk Factors, Survival Analysis, Time Factors, United States epidemiology, Urinary Tract Infections mortality, Kidney Transplantation statistics & numerical data, Postoperative Complications epidemiology, Urinary Tract Infections epidemiology
- Abstract
Background: Although urinary tract infection (UTI) occurring late after renal transplantation has been considered "benign," this has not been confirmed in a national population of renal transplant recipients., Methods: We conducted a retrospective cohort study of 28,942 Medicare primary renal transplant recipients in the United States Renal Data System (USRDS) database from January 1, 1996, through July 31, 2000, assessing Medicare claims for UTI occurring later than 6 months after transplantation based on International Classification of Diseases, 9th Revision (ICD-9), codes and using Cox regression to calculate adjusted hazard ratios (AHRs) for time to death and graft loss (censored for death), respectively., Results: The cumulative incidence of UTI during the first 6 months after renal transplantation was 17% (equivalent for both men and women), and at 3 years was 60% for women and 47% for men (P < 0.001 in Cox regression analysis). Late UTI was significantly associated with an increased risk of subsequent death in Cox regression analysis (P < 0.001; AHR, 2.93; 95% confidence interval [CI], 2.22, 3.85); and AHR for graft loss was 1.85 (95% CI, 1.29, 2.64). The association of UTI with death persisted after adjusting for cardiac and other infectious complications, and regardless of whether UTI was assessed as a composite of outpatient/inpatient claims, primary hospitalized UTI, or solely outpatient UTI., Conclusion: Whether due to a direct effect or as a marker for serious underlying illness, UTI occurring late after renal transplantation, as coded by clinicians in the United States, does not portend a benign outcome.
- Published
- 2004
- Full Text
- View/download PDF
5. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States.
- Author
-
Abbott KC, Sawyers ES, Oliver JD 3rd, Ko CW, Kirk AD, Welch PG, Peters TG, and Agodoa LY
- Subjects
- Analysis of Variance, Black People, Cadaver, Female, Glomerulosclerosis, Focal Segmental complications, Glomerulosclerosis, Focal Segmental ethnology, Humans, Kidney Failure, Chronic etiology, Living Donors, Male, Multivariate Analysis, Recurrence, Registries, Retrospective Studies, Risk Factors, Survival Analysis, Tissue Donors, Treatment Failure, United States epidemiology, White People, Black or African American, Glomerulosclerosis, Focal Segmental epidemiology, Graft Survival, Kidney Failure, Chronic surgery, Kidney Transplantation
- Abstract
Rates of and risk factors for graft loss and graft loss resulting from recurrent focal segmental glomerulosclerosis (FSGS) have not been studied in a national population. A retrospective analysis was performed on a national registry (1999 United States Renal Data System) of 101,808 renal transplant recipients (October 1, 1987, to December 31, 1996). Of these, 3,861 recipients of solitary renal transplants who had end-stage renal disease resulting from FSGS met inclusion criteria. Outcomes were graft loss and graft loss resulting from recurrent FSGS. As a percentage of all graft loss, recurrent FSGS accounted for 18.7% in living donor recipients and 7.8% in cadaveric recipients. In white recipients, the corresponding figures were 27% and 13%. In multivariate analysis, factors associated with graft loss resulting from recurrent FSGS were white recipient, donor African-American kidney in white recipient, younger recipient age, and treatment for rejection. African-American recipients had higher rates of graft loss overall. A living donor was associated with superior overall graft survival. Among renal transplant recipients with FSGS, white recipients had a higher risk of graft loss resulting from recurrent FSGS, disproportionately seen in recipients of African-American kidneys. The role of donor/recipient race pairing on graft loss resulting from recurrent FSGS should be validated. Living donor had no association with graft loss from recurrent FSGS after correction for other factors. African-American recipients with FSGS may have the most to gain from a living donor, given their improved graft survival and decreased risk of graft loss resulting from recurrent FSGS. This is a US government work. There are no restrictions on its use.
- Published
- 2001
- Full Text
- View/download PDF
6. Measuring, managing, and improving quality in the end-stage renal disease treatment setting: committee statement.
- Author
-
Schrier RW, Burrows-Hudson S, Diamond L, Lundin AP, Michael M, Patrick DL, Peters TG, Powe NR, Roberts JS, and Sadler JH
- Subjects
- Humans, Kidney Failure, Chronic therapy, Outcome Assessment, Health Care, United States, Quality of Health Care organization & administration, Renal Replacement Therapy standards
- Abstract
The Institute of Medicine (IOM) committee that organized the conference reported in this issue of the journal on assessing quality of care and quality of life, wishes to emphasize that it regards the task of measuring quality as one that can be approached systematically, albeit with caution. Outcomes of end-stage renal disease (ESRD) care by dialysis and transplantation (and variations of outcomes among treatment units) and related processes of care need to be measured in ways useful to clinicians. In addition to clinical measures of outcome, the committee also favored giving greater attention to functional outcomes and health-related quality of life. The interest in maintaining and improving quality in the treatment setting reflects an underlying need to encourage its systematic assessment on a sustained basis, with appropriate weight devoted to practical issues.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.